Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Blood Test for Peripartum Cardiomyopathy Helps Reduce Mortality

By LabMedica International staff writers
Posted on 27 May 2014
Biomarkers have been discovered that can be used to develop a screening test to detect Peripartum Cardiomyopathy (PPCM), a life-threatening disorder that is the primary cause of mortality in pregnant women in developing countries.

The results of a simple blood test can lead to the immediate treatment of PPCM in new mothers and a significant reduction in mortality, as treatment is often delayed because it is difficult to know whether the women are experiencing normal symptoms of pregnancy or PPCM.

Cardiologists from the Lariboisière Hospital (Paris, France) collected plasma samples from 77 PPCM patients, 75 healthy peripartum women, 25 breast feeding mothers, and 65 nonpregnant acute heart failure (HF) patients. More...
The samples were tested for levels of the cardiovascular N-terminal of the prohormone brain natriuretic peptide (NT-proBNP), anti-soluble fms-like tyrosine kinase-1 (sFlt-1) and angiogenic placental growth factor (PlGF) or vascular endothelial growth factor (VEGF). Samples were measured on either an Abbott Architect system (Abbott laboratories; Abbott Park, IL, USA) or a Cobas Chemistry analyzer (Roche; Basel, Switzerland).

The scientists had hypothesized that since angiogenesis and relaxin-2 pathways are altered in PPCM the biomarkers ratio of these two pathways placental growth factors/sFlt-1 and relaxin-2 could be used to discriminate PPCM among peripartum women. Their results showed that compared to the other groups, PPCM patients had significantly higher levels of NT-proBNP, lower levels of plasma relaxin-2, and that the sFlt-1/PlGF ratio and sFlt-1/VEGF ratio were statistically lower.

Alexandre Mebazaa, MD, PhD, a professor of Anesthesiology and Critical Care Medicine, and coauthor of the study, said, “For pregnant women there are two major causes of death: massive hemorrhage and PPCM, and it is a very sad situation because a time of great happiness turns to great sorrow and the new baby and the father are left alone. We have found a way to detect rather quickly whether the woman has PPCM and to treat it quickly and efficiently.”

Karen Sliwa, MD, PhD, FESC, FACC, DTM&H, a coauthor and professor from the University of Cape Town (South Africa) said, “There's an urgent need for biomarkers of PPCM since the condition can be hard to differentiate from the normal symptoms of pregnancy that include dyspnea, edema and palpitations. The next step will be to confirm our findings in a larger cohort and if they hold we could go on to develop a bed side test similar to NT-pro BNP in heart failure.” The study was presented at the World Congress on Acute Heart Failure during May 17–20, 2014, in Athens (Greece).

Related Links:

Lariboisière Hospital
Abbott laboratories
Roche



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.